Chk
Les inhibiteurs des kinases de point de contrôle (Chk) ciblent les kinases Chk1 et Chk2, qui sont des régulateurs clés de la réponse aux dommages de l'ADN et des points de contrôle du cycle cellulaire. Ces kinases arrêtent la progression du cycle cellulaire en réponse aux dommages de l'ADN, permettant ainsi le temps nécessaire à la réparation. Inhiber les kinases Chk peut empêcher l'arrêt du cycle cellulaire, forçant les cellules endommagées à poursuivre le cycle et à subir finalement l'apoptose. Les inhibiteurs de Chk sont particulièrement précieux dans la recherche sur le cancer, où ils peuvent sensibiliser les cellules tumorales aux agents endommageant l'ADN. Chez CymitQuimica, nous offrons une variété d'inhibiteurs de Chk de haute qualité pour soutenir vos recherches sur la réponse aux dommages de l'ADN, la régulation du cycle cellulaire et l'oncologie.
42 produits trouvés pour "Chk"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Monalizumab
CAS :<p>Monalizumab, a humanized antibody, enhances NK cell function by inhibiting NKG2A; used in HNSCC studies.</p>Degré de pureté :95% - > 95%Couleur et forme :LiquidMasse moléculaire :147 kDa (average)CHK1-IN-4 hydrochloride
<p>CHK1-IN-4 hydrochloride is a potent inhibitor of checkpoint kinase 1 (chk1).</p>Formule :C18H19BrClN7O2Degré de pureté :99.29%Couleur et forme :SoildMasse moléculaire :480.75Zimistobart
CAS :<p>Zimistobart (BMS-986315) is a fully human IgG1 antibody that targets and binds to NKG2A. It is applicable in research for non-small cell lung cancer (NSCLC). For an isotype control, refer to HumanIgG1kappa, Isotype Control.</p>Couleur et forme :LiquidWAY-230563
CAS :<p>WAY-230563 is a serine/threonine kinase inhibitor that blocks CHK1/CHK2-mediated cell cycle checkpoints, leading to G2/M phase arrest in tumour cells</p>Formule :C17H12N2O2SDegré de pureté :98.40%Couleur et forme :SolidMasse moléculaire :308.35CBP501 Affinity Peptide
CAS :<p>CBP501 Affinity Peptide, a Chk kinase inhibitor, disrupts G2 arrest triggered by DNA-damaging agents and is utilized in cancer research [1].</p>Formule :C68H119N21O25SCouleur et forme :SolidMasse moléculaire :1662.86Chk1-IN-6
CAS :<p>Chk1-IN-6 is a potent, selective, and orally bioavailable CHK1 inhibitor candidate.</p>Formule :C16H18F3N7Couleur et forme :SolidMasse moléculaire :365.364CCT241533 dihydrochloride
CAS :<p>Potent Chk2 inhibitor with 3 nM IC50, 63-fold more selective over Chk1, affects 84 kinases, reduces DNA damage response and apoptosis in cells.</p>Formule :C23H29Cl2FN4O4Couleur et forme :SolidMasse moléculaire :515.41CHK1-IN-12
<p>CHK1-IN-12 (Compound example 1-5) is a highly selective and orally active checkpoint kinase 1 (CHK1) inhibitor, demonstrating an in vitro enzyme IC50 of ≤10 nM and a cellular IC50 of ≤50 nM. This compound suppresses the phosphorylation activity of CHK1 kinase, disrupts DNA damage response pathways, and induces tumor cell cycle arrest and apoptosis. CHK1-IN-12 shows promise for cancer research applications.</p>Formule :C19H19N7O2Couleur et forme :SolidMasse moléculaire :377.16002CHK1-IN-9
<p>CHK1-IN-9 (compound 11) is an orally active CHK1 inhibitor with an IC50 of 0.55 nM. It enhances the effects of DNA-damaging agents on tumor cells and exhibits synergistic anticancer activity with Gemcitabine.</p>GDC-0425
CAS :<p>GDC-0425 (RG-7602), an oral selective ChK1 inhibitor, targets multiple cancers.</p>Formule :C18H19N5OCouleur et forme :SolidMasse moléculaire :321.38GDC-0575 dihydrochloride
CAS :<p>GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is a selective, orally active CHK1 inhibitor (IC50: 1.2 nM) that exhibits antitumour effects.</p>Formule :C16H22BrCl2N5OCouleur et forme :SolidMasse moléculaire :451.19CCT244747
CAS :<p>CCT244747 is a potent and selective CHK1 inhibitor oral, ATP-competitive, and cytotoxic, abrogating drug-induced S and G2 blockade and inducing apoptosis .</p>Formule :C20H24N8O2Degré de pureté :99.17%Couleur et forme :SolidMasse moléculaire :408.46GDC0575 monohydrochloride
CAS :<p>GDC0575 (ARRY575), a potent Chk1 inhibitor, IC50 1.2nM, disrupts cell cycle arrest, allowing DNA repair before mitosis.</p>Formule :C16H21BrClN5ODegré de pureté :97.85%Couleur et forme :SolidMasse moléculaire :414.73GDC-0575
CAS :<p>GDC-0575 (ARRY-575) is a highly-selective oral small-molecule Chk1 inhibitor(IC50 of 1.2 nM).</p>Formule :C16H20BrN5ODegré de pureté :≥95%Couleur et forme :SolidMasse moléculaire :378.27SAR-020106
CAS :<p>SAR-020106 is a potent, ATP-competitive, and selective CHK1 inhibitor with an IC50 of 13.3 nmol/L on the isolated human enzyme.</p>Formule :C19H19ClN6ODegré de pureté :97.78%Couleur et forme :SolidMasse moléculaire :382.85LY2880070
CAS :<p>LY2880070 is a new checkpoint kinase 1 (CHK1) inhibitor for cancer therapy.</p>Formule :C19H23N7O2Degré de pureté :99.77%Couleur et forme :SolidMasse moléculaire :381.43CCT245737
CAS :<p>CCT245737 is an orally active, selective Chk1 inhibitor, and is >1,000-fold selective over CHK2 and CDK1.Cost-effective and quality-assured.</p>Formule :C16H16F3N7ODegré de pureté :98.06% - 99.69%Couleur et forme :SolidMasse moléculaire :379.34SCH900776
CAS :<p>SCH900776 (MK-8776) is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities.</p>Formule :C15H18BrN7Degré de pureté :96.69% - 99.6%Couleur et forme :SolidMasse moléculaire :376.25Rabusertib
CAS :<p>Rabusertib (IC-83) is a chk1 inhibitor in trials for various cancers, including pancreatic and non-small cell lung cancer.</p>Formule :C18H22BrN5O3Degré de pureté :98.86% - 99.87%Couleur et forme :SolidMasse moléculaire :436.3AZD-7762
CAS :<p>AZD-7762, an effective and specific inhibitor of Chk1（IC50=5 nM）, is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck.</p>Formule :C17H19FN4O2SDegré de pureté :98.96% - 99.19%Couleur et forme :SolidMasse moléculaire :362.42
